Table 1.
The clinical information of CMML patients classified as MD/MP subtypes
| Variables | Total CMML (n = 178) |
MD-CMML (n = 83) |
MP-CMML (n = 95) |
P value |
|---|---|---|---|---|
| Age in years; median (range) | 62 (17–90) | 63 (24–90) | 60 (17–85) | 0.362 |
| Sex (male); n (%) | 118 (66.3%) | 54 (65.1%) | 64 (67.4%) | 0.745 |
| Hemoglobin g/L; median (range) | 85 (38–173) | 85 (38–140) | 87 (40–173) | 0.410 |
| ANC ×109/L; median (range) | 4.75 (0.45–29.97) | 2.17 (0.45–6.15) | 10.9 (1.14–29.97) | 0.000 |
| AMC ×109/L; median (range) | 2.43 (1.01–16.32) | 1.8 (1.01–5.69) | 3.23 (1.11–16.32) | 0.002 |
| Platelets×109/L; median (range) | 76 (3–977) | 69 (11–900) | 85 (3–977) | 0.828 |
| LDH IU/ml; median (range) | 279.1 (120–1403) | 224.6 (120–977.1) | 333.5 (152.4–1403) | 0.008 |
| Cytogenetic risk groupa n (%) | 0.032 | |||
| Low-risk | 129 (72.5%) | 66 (79.5%) | 63 (66.3%) | 0.049 |
| Intermediate-risk | 18 (10.1%) | 9 (10.8%) | 9 (9.5%) | 0.762 |
| High-risk | 31 (17.4%) | 8 (9.7%) | 23 (24.2%) | 0.011 |
| Splenomegaly ; n (%) | 42 (28.4%) | 13 (19.6%) | 29 (35.3%) | 0.036 |
| Treatment strategy; n (%) | 0.821 | |||
| Best supportive care | 28 (30.4%) | 12 (28.6%) | 16 (32.0%) | |
| HMAs ± chemotherapy/allo-HSCT | 64 (69.6%) | 30 (71.4%) | 34 (68.0%) | |
FAB classification MD-CMML: WBC < 13 × 109/L, (109: 9 needs to be superscripted) MP-CMML: WBC ≥ 13 × 109/L (109: 9 needs to be superscripted)
LDH: Lactate dehydrogenase
aCytogenetic risk groups [1, 2]: low-risk: a diploid karyotype or -Y; high-risk: trisomy 8, alterations of chromosome 7, as well as complex karyotype; intermediate-risk: all other karyotypes